Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test"
EBioMedicine
.
2020 Dec:62:103139.
doi: 10.1016/j.ebiom.2020.103139.
Epub 2020 Nov 27.
Authors
Thomas Weiland
1
,
Luka Brcic
2
,
Markus Reinholz
3
,
Lars E French
3
,
Dietmar Thurnher
4
Affiliations
1
Department of Otorhinolaryngology-Head&Neck Surgery, Medical University of Graz, Graz, Austria. Electronic address: thomas.weiland@medunigraz.at.
2
Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
3
Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
4
Department of Otorhinolaryngology-Head&Neck Surgery, Medical University of Graz, Graz, Austria.
PMID:
33254024
PMCID:
PMC7701314
DOI:
10.1016/j.ebiom.2020.103139
No abstract available
Publication types
Comment
MeSH terms
Capsid Proteins
Early Detection of Cancer*
Human papillomavirus 16 / genetics
Humans
Neoplasms* / diagnosis
Substances
Capsid Proteins